HDAC9 and breast carcinoma: Since sustained, non-lethal levels of UPR permit cancer cells to survive and continue to grow despite hostile internal and external conditions that include nutrient and lipid deprivation and hypoxia62, HDAC/DNMT inhibitors may increase breast cancer risk in individuals not exposed to in utero manipulations by upregulating UPR.